NOL7 Inhibits Ovarian Cancer Progression and Suppresses Angiogenesis by Stabilizing GADD45A to Deactivate STAT3

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Ovarian cancer is a leading gynecologic malignancy with complex pathogenesis involving cell proliferation and angiogenesis.
• Nucleolar Protein 7 (NOL7), an RNA-binding protein, is implicated as a tumor suppressor and anti-angiogenic factor, but its role in ovarian cancer is not fully understood.

Purpose of the Study:

• To investigate the function and molecular mechanisms of Nucleolar Protein 7 (NOL7) in ovarian cancer.
• To determine the prognostic value of NOL7 expression in ovarian cancer patients.

Main Methods:

• Assessed NOL7 expression in ovarian cancer tissues and correlated it with patient prognosis.
• Utilized cell culture (OVCAR-3, SKOV-3, HUVECs) and in vivo models to study the effects of NOL7 overexpression and knockdown on cancer cell behavior and angiogenesis.
• Performed mechanistic studies involving RNA-binding assays, mRNA stability analysis, and Western blotting to elucidate the NOL7 signaling pathway.

Main Results:

• NOL7 expression was significantly downregulated in ovarian cancer tissues, with lower levels associated with poorer patient prognosis.
• Overexpression of NOL7 inhibited ovarian cancer cell proliferation, viability, and angiogenesis, while promoting apoptosis. Conversely, NOL7 knockdown enhanced these processes.
• NOL7 directly binds to the 3'UTR of GADD45A, upregulating its expression by stabilizing its mRNA. The anti-cancer effects were mediated through the NOL7/GADD45A pathway by inhibiting STAT3 phosphorylation.

Conclusions:

• NOL7 functions as a crucial tumor suppressor in ovarian cancer.
• NOL7 inhibits ovarian cancer progression and angiogenesis via the GADD45A/STAT3 signaling axis.
• NOL7 represents a potential novel therapeutic target for ovarian cancer treatment.